17:45 , Mar 30, 2018 |  BC Week In Review  |  Clinical News

Northwestern researchers report Phase III MS data for HSCT vs. continuing disease-modifying therapies

Researchers at Northwestern University and colleagues reported data from a Phase III trial in 110 patients with highly active relapsing-remitting multiple sclerosis (MS) showing that conditioning with cyclophosphamide and rabbit anti-thymocyte globulin followed by non-myeloablative...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
01:38 , Jan 3, 2018 |  BC Extra  |  Company News

Allergan among companies unveiling price hikes

Allergan plc (NYSE:AGN) raised the price of 18 drugs by 9.5%, just under the company's pledge to limit yearly price increases to single digits, according to a Jefferies report. Allergan spokesperson Mark Marmur told BioCentury...
02:50 , Dec 8, 2017 |  BC Week In Review  |  Company News

Biogen agrees to outcomes-based contract for MS portfolio

Biogen Inc. (NASDAQ:BIIB) signed an outcomes-based contract with PBM Prime Therapeutics LLC (Eagan, Minn.) for Biogen's multiple sclerosis drugs under Prime's CareCentered Contract program. Prime VP of Pharmaceutical Trade Relations Susan Scheid told BioCentury the...
23:13 , Dec 1, 2017 |  BC Extra  |  Company News

Biogen agrees to outcomes-based contract for MS portfolio

Biogen Inc. (NASDAQ:BIIB) signed an outcomes-based contract with PBM Prime Therapeutics LLC for Biogen's multiple sclerosis drugs under Prime's CareCentered Contract program. Prime Therapeutics VP of Pharmaceutical Trade Relations Susan Scheid told BioCentury the contract...
21:25 , Nov 10, 2017 |  BC Week In Review  |  Clinical News

Novartis reports final Phase III data of Gilenya in pediatric MS

Novartis AG (NYSE:NVS; SIX:NOVN) reported final data from the Phase III PARADIGMS trial in 215 patients ages 10-17 with multiple sclerosis showing that once-daily oral Gilenya (Imusera) fingolimod (FTY720) reduced annualized relapse rate (ARR) over...
06:29 , Nov 3, 2017 |  BC Week In Review  |  Clinical News

Celgene reports detailed Phase III data for MS candidate ozanimod

Celgene Corp. (NASDAQ:CELG) reported detailed data from the double-blind, international Phase III SUNBEAM and RADIANCE trials of oral ozanimod (RPC1063) to treat relapsing multiple sclerosis. Ozanimod is the next closest launch in Celgene’s pipeline after...
23:11 , Oct 30, 2017 |  BC Extra  |  Clinical News

Celgene reports detailed Phase III data for MS candidate ozanimod

Celgene Corp. (NASDAQ:CELG) reported detailed data from the Phase III SUNBEAM and RADIANCE trials of oral ozanimod ( RPC1063 ) to treat relapsing multiple sclerosis. Ozanimod is the next closest launch in Celgene’s pipeline after...
02:00 , Oct 28, 2017 |  BioCentury  |  Strategy

Biogen doubles down

Shares of Biogen Inc. were buffeted last week by a pair of poorly understood moves intended to improve the big biotech’s share of profits for aducanumab, along with lower than expected revenues for newly launched...
21:25 , Sep 29, 2017 |  BC Week In Review  |  Clinical News

Novartis' Gilenya meets in Phase III for pediatric MS

Novartis AG (NYSE:NVS; SIX:NOVN) reported top-line data from the Phase III PARADIGMS trial in 215 patients ages 10-17 with multiple sclerosis showing that once-daily oral Gilenya (Imusera) fingolimod (FTY720) met the primary endpoint of reducing...